To compare the six-month clinical results of ranibizumab with aflibercept for the treatment of wet age-related macular degeneration (wet-AMD).


Medical records of 44 eyes of 44 patients who underwent intravitreal ranibizumab (0.5mg / 0.05ml) or aflibercept (2.0mg / 0.05ml) injection for wet-AMD with more than 6 months of follow-up were reviewed retrospectively. All patients were treated with an initial series of three monthly intravitreal anti-VEGF injections, followed by as-needed injections. The best corrected visual acuity (BCVA), central macular thickness (CMT) and the number of injections were compared at baseline and 6 months.


The average number of injections for six months in ranibizumab group was 3.36 ± 0.65 times, in aflibercept group was 3.50 ± 0.67 times (p=0.500). The mean BCVA (logMAR) in ranibizumab group was 0.75 ± 0.55, and 0.53 ± 0.49 at baseline and 6 months, respectively (p=0.003). The mean BCVA in aflibercept group was 0.64 ± 0.61, and 0.46 ± 0.55 at baseline and 6 months, respectively (p<0.001). The mean CMT (um) in ranibizumab group was 406.2 ± 70.9, and 249.9 ± 45.2 at baseline and 6 months, respectively (p<0.001). The mean CMT (um) in aflibercept group was 479.4 ± 59.2, and 267.1 ± 43.5 at baseline and 6 months, respectively (p<0.001).


In wet AMD, intravitreal ranibizumab and aflibercept treatment had equivalent effects on vision improvement and reduction of CMT.

Contact Details:

Email: idoc@kimeye.com
Cell Phone: +821032241675

Oh Jae Kim